Brainstorm Cell Therapeutics Inc (OTC:BCLI) announced that its stem cell treatment for neurodegenerative diseases has been shown to treat better than other potential stem cell treatments. The study was published in the Israel Medical Association Journal by Ofer Sadan, Eldad Melamed, and Daniel Offen, from Tel Aviv University. Since the technology is clinically compatible and safe, stem cells will most likely become the preferred choice for the treatment of neurodegenerative diseases.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Brainstorm Cell Therapeutics Inc is engaged in the development of stem cell therapeutic products. The products are focused on technologies that enable in-vetro differentiation of bone marrow stem cells to neural-like cells. Brainstorm technology is based on NurOwn products that extract bone marrow and process it into neuronal-like cells to re-implant in the muscles, or brain.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
